Study of antibacterial and antibiofilm activity of Bacteriocin in patients with Acinitobacter baumannii chest infection antibacterial and antibiofilm activity of Bacteriocin in patients with Acinitobacter baumannii
Article Sidebar
Main Article Content
Abstract
Abstract
Acinetobacter baumannii is a Gram-negative opportunistic bacterium associated with nosocomial and community-acquired illnesses. This pathogen is rapidly expanding on a global scale and is linked to the development of resistance against numerous antibiotics. Therefore, this research aims to investigate the activities of bacteriocin as antibacterial and antibiofilm against Acinetobacter baumannii. Sputum specimens were collected from sixty patients with respiratory tract infections admitted to the respiratory care unit in three hospitals in Baghdad. Acinetobacter baumannii was isolated and identified using biochemical tests, and the diagnosis of the isolates was validated. An antibiotic susceptibility test was conducted using the VITEC 2 systems. Biofilm formation was detected using a microtiter plate assay. Bacteriocin extract from Lactobacillus was employed to assess antibiofilm activity via the microtiter plate method, while antibacterial activity was determined using the agar well diffusion method. The results showed that the prevalence of Acinetobacter baumannii was 30% among Iraqi samples. In this study, Acinetobacter baumannii showed higher overall resistance to most antibiotics (100%). In addition, the overall sensitivity for colistin antibiotic was (100%), accompanied with good inhibitory effect against A. buamannii growth that associated with a definitive effect on biofilm production by this bacteria. In conclusion, the study approved the validity of bacteriocin against Acinetobacter baumannii. The authors suggests the possibility of utilization of bacteriocine as effective adjuvants and bio control agents for treatment and eliminating multidrug bacteria using the novel technique.
Article Details
This work is licensed under a Creative Commons Attribution-ShareAlike 4.0 International License.
The Journal of Medical and Oral Biosciences uses a Creative Commons Attribution (CC Attribution-ShareAlike 4.0) and its license of (CC BY-SA 4.0). This license allows the authors to hold ownership of the copyright of their articles.
Attribution-Share Alike 4.0 International License (CC BY-SA 4.0). 
Under the CC BY-SA 4.0 the authors are free to:
Share — copy and redistribute the material in any medium or format for any purpose, even commercially.
Adapt — remix, transform, and build upon the material for any purpose, even commercially.
The licensor cannot revoke these freedoms as long as you follow the license terms.
Under the following terms:
Attribution — You must give appropriate credit, provide a link to the license, and indicate if changes were made. You may do so in any reasonable manner, but not in any way that suggests the licensor endorses you or your use.
ShareAlike — If you remix, transform, or build upon the material, you must distribute your contributions under the same license as the original.
No additional restrictions — You may not apply legal terms or technological measures that legally restrict others from doing anything the license permits.
No use, distribution or reproduction is permitted which does not comply with these terms.
https://creativecommons.org/licenses/by-sa/4.0/